King Charles House
Park End Street
About Evox Therapeutics
Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of biotherapeutics.
Founders: Matthew Wood, Per Lundin and Samir EL Andaloussi
CEO: Antonin de Fougerolles
COO: Per Lundin
8 articles with Evox Therapeutics
Evox Therapeutics Expands Leadership Team With the Appointment of Two Experienced Life Sciences Executives
Evox Therapeutics Ltd, a leading exosome therapeutics company, is pleased to announce the appointments of Bo Kara as VP Process Development and Simon Dew as VP of Business Development.
Proceeds will support advancement of an exosome therapy to treat a urea cycle disorder
Highly experienced life sciences executive with a track record of overseeing strong company growth and value creation
Funding received from the Bill & Melinda Gates Foundation
Prestigious accolade recognises the potential impact of the Company's disruptive exosome drug platform
Targeted delivery of dystrophin has the potential to be a highly effective treatment for Duchenne muscular dystrophy
Proceeds will advance transformative exosome therapeutics pipeline towards the clinic
The collaboration is part of Boehringer Ingelheim's RBB initiative that explores emerging science and technologies for and beyond its core therapeutic areas to create new opportunities in disease indications of high medical need.